AI Article Synopsis
- FOLFIRINOX is more effective than gemcitabine for treating pancreatic cancer, but it comes with higher toxicity levels and the need for biomarkers to predict patient responses.
- Certain microRNAs, specifically miR-21-5p, miR-10b-5p, and miR-34a-5p, are linked to resistance against gemcitabine, but their expression levels do not significantly impact outcomes for FOLFIRINOX treatment.
- A study involving 29 patients shows that the combination of chemotherapy in FOLFIRINOX can potentially counteract some negative prognostic factors associated with advanced pancreatic cancer.
Article Abstract
FOLFIRINOX is superior to gemcitabine in patients with pancreatic cancer, but this regimen is associated with toxicity and biomarkers for response are warranted. MicroRNAs can mediate drug resistance and could provide predictive information. Altered expressions of several microRNAs including miR-21-5p, miR-10b-5p and miR-34a-5p have been previously linked to a worse response to gemcitabine. We investigated the influence of expression levels in tumor tissue of those three microRNAs on outcome to FOLFIRINOX. Twenty-nine patients with sufficient formalin-fixed paraffin-embedded tumor tissue were identified. There was no significant association between high and low expression groups for these three microRNA. We conclude that polychemotherapy combination can overcome intrinsic negative prognostic factors.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7787156 | PMC |
| http://dx.doi.org/10.2144/fsoa-2020-0128 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!